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ABSTRACT 
The oral route is increasingly being used for the delivery of therapeutic agents because the low cost of the therapy and ease of administration 
lead to high level of patient compliances.  Floating drug delivery system (FDDS) float in the gastric fluid and prolong GRT to obtain sufficient drug 
bioavailability, because of their lower bulk density compared to that of the aqueous medium. The aim of the present study is to prepare floating 
tablets as a delivery system for controlled release of Ketoconazole. Ketoconazole is a drug of choice in antifungal category and gives significant 
result. Floating tablets containing Ketoconazole were prepared by direct compression technique using varying concentrations of different grades 
of polymers of Hydrxy Propyl Cellulose & Xanthan gum. To evaluate the prepared floating tablets for various parameters like hardness, friability, 
uniformity of drug content, in-vitro floating studies, in-vitro dissolution studies. 
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INTRODUCTION 
Oral route was one of the most convenient and preferable 
ways for drug administration. More than 50% of the drug 
delivery systems available in the market are oral drug 
delivery systems. Controlled-Release drug delivery system 
(CRDDS) provides drug release at a predetermined, 
predictable and controlled rate. Controlled-Release drug 
delivery system is capable of achieving the benefits like 
maintenance of optimum therapeutic drug concentration in 
blood with predictable and reproducible release rates for 
extended time period: enhancement of activity of duration 
for short half-life drugs elimination of side effect*s: reducing 
frequency of dosing and wastage of drugs: optimized therapy 
and better patient compliances. Gastro retentive systems can 
remain in the gastric region for several hours and hence 
significantly prolong the gastric residence time of drugs. 
Prolong gastric retention improves bioavailability, reduces 
drug waste and improves solubility for drugs that are less 
soluble in high pH environment. Floating systems or hydro 
dynamically balanced systems are low-density systems that 
have sufficiently buoyancy to float over the gastric contents 
and remain buoyant in the stomach without affecting the 
gastric emptying rate for a prolonged period of time and a 
better control of the fluctuations in plasma drug 
concentrations.1-7 
METHODS 
Preformulation 8-10 
Characterization of Drug:  
Physiochemical Properties of Ketoconazole 
Organoleptic evaluation  
It was done by evaluation of sensory characters like taste, 
appearance, odor etc. 
Solubility (at room temperature):  
Solubility can be defined as the property of a solute (solid, 
liquid, or gaseous chemical substance) to dissolve in a solid, 
liquid, or gaseous solvent to form a identical solution of the 
solute in the solvent. The solubility of a substance is the 
quantity of that solute that will dissolve in a given quantity of 
solvent. It is a important parameter for dosage form 
designing. 
Procedure: 
Approximately 1 gram of drug was weighed accurately and 
transferred to 5 different 10 ml. volumetric flasks. Different 
solvents (DCM, ether, water, Ethanol, Methanol, Chloroform) 
were added to the flask respectively and the solubility was 
observed. 
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Melting point:  
It is one of the parameters for the purity of drugs.  In case of 
pure chemicals, melting points are very sharp and constant.  
Since the drugs contain the mixed chemicals, they are 
described with certain range of melting point. 
Procedure for determine melting point: 
A small quantity of drug was placed into a capillary tube, and 
then it was placed in the melting point determining 
apparatus containing liquid paraffin. The temperature of the 
liquid paraffin was gradual increased automatically and 
reading was taken at which sample started to melt till all 
sample gets melted. 
Bulk Properties: 
Bulk density is defined as the mass of powder divided by the 
bulk volume. Bulk density largely depends on particle shape, 
as the particles become more spherical in shape, bulk density 
is increase. In addition as granules size increase, bulk density 
decrease. Bulk properties such as particle size, bulk density 
etc. of a solid form, are likely to change during process 
development. Therefore, comprehensive characterization of 
all Preformulation lots is necessary to avoid misleading 
predictions. 
Bulk density is determined by measuring the volume of a 
known mass of powder sample that has been passed through 
a screen into a graduated cylinder or through a volumetric 
measuring apparatus into a cup. 
Procedure: 
Approximately 4 gram of powdered drug was accurately 
weighed and poured into the measuring cylinder carefully 
and level of the powdered drug without compacting was 
recorded. After that powdered drug was compressed by 
tapping the measuring cylinder for around 50 times on the 
palm and the compressed level was recorded. Finally the 
Bulk density was calculated in gm per ml gm/cc, by the 
formula: 
Bulk density = Bulk Mass/ Bulk Volume 
Table 1: Bulk Density of Ketoconazole 
S. 
No. 
Density Ketoconazole 
1 Untapped  Density 0.714g/cc 
2 Tapped Density (after 50 
tapping) 
0.769g/cc 
 
(H) Compressibility index (Carr’s index):  
Compressibility index (C.I.) is an important measure that can 
be obtained from the bulk and tapped densities. Carr’s index 
a material having values of less than 20% to 30% is defined 
as the free flowing material. It can be calculated as per given 
formula:
 
 
                       100 (V0-Vf)                                                            Tapped density- Bulk density 
                 C.I. =                   OR                          C.I. =      x100              
                                             V0                                                                          Tapped density 
 
Table 2: Carr’s index range 
S. No. % Comp. Index Properties 
1 5-12 Excellent 
2 12-16 Good 
3 18-21 Fair – passable 
4 23-25 Poor 
5 33-38 Very Poor 
6 >40 Extremely poor 
 
Determination of λ max of Ketoconazole 
The absorption maxima of ketoconazole was determined by 
running the spectrum of drug solution in double beam 
ultraviolet spectrophotometer. 
Calibration curve of Ketoconazole 
Preparation of Standard Stock Solution: 
10mg of ketoconazole was weighed accurately and 
transferred to 10 ml volumetric flask, and the volume was 
adjusted to the mark with the 0.1 N Hcl to give a stock 
solution of 1000 ppm or µg/ml. 
Preparation of Working Standard Solution:- 
From stock solutions of Ketoconazole 1 ml was taken and 
diluted up to 10 ml separate volumetric flask. From this 
solution 0.5, 1.0, 1.5, 2.0 and 2.5 ml solutions were 
transferred to 10ml volumetric flasks and make up the 
volume up to 10 ml with mobile phase, gives standard drug 
solution of 5, 10, 15, 20, 25µg/ml concentrations of 
Ketoconazole. 
Formulation Development 12-14 
Preparation of Floating tablets10-11  
Floating tablets containing Ketoconazole were 
prepared by direct compression technique 
using varying concentrations of different grades of 
polymers of HPC & Xanthan gum with sodium 
bicarbonate, citric acid, Lactose are geometrically mixed 
all the powders were passed through sieve. No #80. 
Magnesium stearate and talc were finally added as 
glidant and lubricant respectively. The blend was 
directly compressed using tablet compression machine. 
The tablets were off white, round and flat. The hardness 
of the tablets was kept constant. Ten formulations 
were prepared and coded them from F1 to F10.  
Evaluation of Pre-compression Parameter  
1. Angle of repose (θ):  The frictional forces in a loose 
powder or granules can be measured by the angle of 
repose. This is the  maximum  angle  possible  between  
the  surface  of  a  pile  of powder or granules and the 
horizontal plane.  
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Where,  θ is  the  angle  of  repose,  h  is  the  height,  r  is  the 
radius.  
The  granules  were  allowed  to  flow  through  the  funnel 
fixed  to  a  stand  at  definit height. The  angle  of  repose was  
then calculated  by  measuring  the  height  and  radius  of  
the  heap  of granules formed 
 Table 3: Relationship between Angle of Repose (θ) and flow properties  
S. No. 
Angle of Repose (θ) 
(degrees) 
Flow 
1. <25 Excellent 
2. 25-30 Good 
3. 30-40 Passable* 
4. >40 Very poor 
*Adding glidant E.g. Talc may improve flow properties   
2. Bulk density:  Both loose bulk density (LBD) and 
tapped bulk density (TBD) were determined. Accurately 
weighed amount of granules  taken  in a 50 ml capacity 
measuring cylinder was  tapped for  100  times  on  a  
plane  hard wooden  surface  and  estimated  the LBD  
and  TBD,  calculated  by  using  following  formulas. 
 
 
 
 
3. Carr’s Compressibility  index:  Percent  
compressibility  of  powder mix was determined by 
Carr’s compressibility index, calculated by using 
following formula:- 
 
 
 
Table 4: Grading of the powders for their flow properties 
according to Carr’s Index 
S. No. Carr’s Compressibility  index Flow 
1. 5 – 15 Excellent 
2. 12 – 16 Good 
3. *18 – 21 Fair to passable 
4. *23 – 35 Poor 
5. 33 – 38 Very poor 
6. >40 Very very poor 
*Adding glidant E.g. Talc should improve the flow properties 
4. Hausners ratio: It  is determined by comparing tapped 
density to the bulk density by using following equation:- 
             
 Housner’s ratio = Tapped bulk density/loose Bulk 
density 
Hausner’s ratio value <1.25 shows better flow properties  
 Evaluation of post compression Parameter15-16 
1. Shape and colour of tablets: 
Uncoated tablets were examined under a lens for the shape 
of the tablet and colour was observed by keeping the tablets 
in light. 
2. Thickness test 
Three tablets were picked from each formulation randomly 
and thickness was measured individually. It is expressed in 
mm and standard deviation was also calculated. The tablet 
thickness was measured using dial-caliper (Mitutoyo, Japan). 
3. Weight variation test 
Twenty tablets were selected randomly from each 
formulation and average weight was determined.  The 
tablets were weighed individually and compared with 
average weight. The U.S Pharmacopoeia allows a little 
variation in the weight of a tablet. The following percentage 
deviation in weight variation is allowed  
 
Table 5: Percentage deviation in weight variation 
 
S. 
no. 
Average weight of a tablet 
Percentage 
deviation 
1. 130 mg or less 10 
2. 
More than 130 mg and less than 
324 mg 
7.5 
3. 324 mg or more 5 
 
In all the formulations the tablets weight is more than 130 
mg and less than 324 mg, hence 7.5% maximum difference 
allowed. 
4. Hardness test 
The hardness of tablet was measured by Pfizer hardness 
tester and results were expressed in Kg/cm2. 
5. Friability test 
For this, 20 tablets were taken from each formulation and 
the friability was determined using Roche friabilator. The 
equipment was run for 4min at 25 revolutions per minute. 
The tablets were taken out, dedusted and reweighted and % 
friability was calculated. The friability was determined as the 
mass loss in percent according to Equation:- 
 
The test complies if tablets not loose more than 1% of their 
weight 
6. Uniformity of drug content:  
The test is mandatory for tablets. Ten randomly selected 
tablets from each formulation (F1 to F10) were finely 
powdered and Drug equivalent  to  10  mg of drug dissolved 
in 10 ml  0.1  N  HCl  (simulated gastric ﬂuid  of pH 1.2 
without enzymes) sonicate it for 20 minutes, then  the  
solution was  filtered  through  whatman  filter  paper No. 41. 
From this Solution take 1 ml and Diluted up to 100 ml with 
0.1 N HCl and the drug content was determined 
spectrophotometrically at 222.00 nm for Ketoconazole.  
Method for Preparation of Ketoconazole Floating tablet: 
Direct compression was followed to manufacture the gas 
generating floating tablets of Ondansetron Hydrochloride. 
Nine different formulations (F1, F2, F3, F4, F5, F6, F7, F8, 
F9 & F10) were prepared by direct compression. All the 
polymers selected, drug and excipients were passed through 
sieve no. 40 before using into formulation. The amount and 
ratio of drug and polymers were weighed and all the 
formulations were used for further evaluations parameters. 
Excipients like Sodium bicarbonate, citric acid anhydrous, 
Magnesium Stearate were selected for the study. Sodium 
bicarbonate and citric acid were used as gas generating 
agent. Citric acid was also used as an antioxidant. Steps 
involved in the manufacture of tablets, first the drug, 
polymer and other excipients selected were passed 
through 40- mesh sieve. Required quantity of drug, polymer 
and excipients were weighed properly and transferred into 
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polyethylene bag and the blend was mixed for at least 15 
min. The blend obtained was then lubricated by adding 
1% magnesium stearate and again mixed for another 5min. 
Evaluation of tablets: 
All the tablets were evaluated for following different 
parameters which includes; 
General Appearance  
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, shape, 
were evaluated. Appearance was judged visually. Very good 
(+++), good (++), fair (+) poor (-), very poor (- -). 
Thickness and diameter  
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used, and 
an average value was calculated. 
Drug content  
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N Hcl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and react with dye and analyzed for drug 
content by UV spectrophotometer at a λ max of 414.0 nm 
using of 0.1 N HCl as blank. 
Hardness  
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Friability  
The friability of a sample of 10 tablets was measured using a 
Friability tester (Electro Lab). Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
 Uniformity of weight  
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
In vitro buoyancy studies: 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al. The tablets were placed 
separately in a 100 ml glass beaker containing 2simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time required for 
the tablet to rise to the surface and float was determined as 
floating lag time. 
Dissolution rate studies 
 In vitro drug release of the sample was carried out using 
USP- type II dissolution apparatus (Paddle type). The 
dissolution medium, 900 ml 0.1N HCl was placed into the 
dissolution flask maintaining the temperature of 37±0.50c 
and rpm of 75. One Ketoconazole tablet was placed in each 
basket of dissolution apparatus. The apparatus was allowed 
to run for 10 hours. Sample measuring 5 ml were withdrawn 
after every 1 hour up to 10 hours using 10ml pipette. The 
fresh dissolution medium (370C) was replaced every time 
with the same quantity of the sample. From this take 0.5 ml 
and dilute up to 10 ml with 0.1 N HCL and take the 
absorbance at 222.0 nm using spectroscopy. 
 
Figure 1: Photographs taken during in-vitro Dissolution 
study of floating Tablets in 0.1 N HCL. 
RESULTS 
Preformulation  
Characterization of Drug:  
Physiochemical Properties of Ketoconazole 
It was found white crystalline powder, Odorless & tasteless. 
Solubility (at room temperature):  
Table 6: Solubility studies of Ketoconazole 
S.No. Solvent Solubility 
1 Dichloromethane Freely Soluble 
2 Chloroform Soluble 
3 Methanol Soluble 
4 Ethanol (95%) sparingly soluble 
5 Water Practically insoluble 
6 Ether Slightly soluble 
 
It was found that ketoconazole was practically insoluble in 
water; freely soluble in DCM, soluble in chloroform & 
methanol, slightly soluble in ether. 
Melting point:  
Melting point was determined by Melting point apparatus 
and found to be 148-1520C. 
Bulk Properties: 
Bulk density of powder was found to be 0.833g/cc and 
0.714g/cc for ketoconazole. 
 
Table 7: Bulk Density of Ketoconazole 
S. 
No. 
Density Ketoconazole 
1 Untapped  Density 0.714g/cc 
2 Tapped Density (after 50 
tapping) 
0.769g/cc 
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The compressibility index of Ketoconazole was found to be 
8.360% and 7.152%. 
M)  Determination of λ max of Ketoconazole 
The absorption maxima of ketoconazole was determined by 
running the spectrum of drug solution in double beam 
ultraviolet spectrophotometer. 
 
Figure 2: Determination of λ max of Ketoconazole 
 
Calibration curve of Ketoconazole 
 
Figure 3: Calibration Curve of Ketoconazole
 
 
Method for Preparation of Ketoconazole Floating tablet: 
Table 8: Composition of Ketoconazole Tablets 
Ingredients (mg) 
Formulation code 
F1 F 2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 F 10 
Ketoconazole 200 200 200 200 200 200 200 200 200 200 
HPC 100 200 300 _ _ _ 50 100 50 100 
Xanthan gum _ _ _ 100 200 300 50 100 50 100 
Sodium bicarbonate 50 50 50 50 50 50 50 50 100 100 
Citric acid 25 25 25 25 25 25 25 25 25 25 
Lactose 260 160 60 260 160 60 260 160 210 110 
Magnesium stearate 5 5 5 5 5 5 5 5 5 5 
Talc 10 10 10 10 10 10    10 10 10 10 
Total weight (mg) 650 650 650 650 650 650 650 650 650 650 
 
Evaluation of Precompression Parameter 
Table 9: Results of pre-compressional parameters of Ketoconazole 
Formulation 
code 
Parameters 
Loose Bulk 
density(gm/ml) 
Tapped bulk 
density(gm/ml) 
Carr’s Index 
(%) 
Hausner’s 
Ratio 
Angle of 
Repose 
F1 0.34 0.43 20.93 1.26 42025 
F2 0.33 0.42 21.43 1.27 42025 
F3 0.34 0.43 20.93 1.26 41036 
F4 0.35 0.4 12.50 1.14 42026 
F5 0.34 0.43 20.93 1.26 43015 
F6 0.33 0.41 19.51 1.24 43036 
F7 0.34 0.42 19.05 1.24 40056 
F8 0.35 0.43 18.60 1.23 41026 
F9 0.34 0.41 17.07 1.21 40023 
F10 0.31 0.43 17.02 1.20 40021 
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Evaluation of post compression Parameter 
Table 10: Results of Post-Compression parameters of all formulations 
F. Code Hardness 
test (kg/cm2) 
Friability 
(%) 
Weight  variation 
(%) 
Thickness 
(mm) 
Drug content (%) 
 
F1 3.13  0.8217 Passes 1.42  99.41 
F2 3.10  0.7262  Passes 1.45  99.77 
F3 3.11  0.5314  Passes 1.41  98.53 
F4 3.13  0.6425  Passes 1.40 99.41 
F5 3.11  0.6346  Passes 1.44  99.33 
F6 3.21  0.7114  Passes 1.46  98.51 
F7 3.26  0.5612  Passes 1.40  99.57 
F8 3.27  0.8554  Passes 1.43  98.33 
F9 3.12 0.7377  Passes 1.42  99.65 
F10 3.21  0.7114  Passes 1.46  98.51 
 
Method for Preparation of Ketoconazole Floating tablet: 
Table 11: Result of Pre-Compression Properties of Ketoconazole Floating Tablets 
Material Angle of 
repose(Degree) 
Bulk 
density(gm/ml) 
Tapped 
density(gm/ml) 
Compressibility 
index 
Hausner 
ratio 
Ketoconazole  
F1 30.31 0.582 0.732 27.33 0.721 
F2 29.35 0.581 0.730 28.33 0.723 
F3 27.82 0.576 0.728 27.30 0.720 
F4 30.69 0.570 0.729 29.30 0.726 
F5 28.30 0.580 0.735 30.30 0.730 
F6 30.28 0.585 0.732 32.80 0.728 
F7 28.46 0.582± 0.742 36.24 0.720 
F8 29.49 0.579 0.792 29.72 0.720 
F9 30.13 0.584 0.768 28.52 0.739 
F10 30.05 0.581 0.759 27.45 0.725 
 
Evaluation of tablets: 
All the tablets were evaluated for following different parameters which includes; 
Table 12: Results of Post Compression Properties of Ketoconazole Floating tablets 
Formulation 
code 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
Weight 
variation (mg) 
Friability (%) Drug content 
(%) 
F1 3.53 4.8 300.19 0.58  98.33 
F2 3.94 4.4 300.18  0.51  97.20  
F3 3.96 4.5 300.33  0.38  99.60  
F4 3.95 4.7 300.30 0.16  98.14  
F5 3.93 5.2 300.13 0.31  97.21  
F6 4.03 5.3 300.16 0.27  97.50 
F7 4.05 4.8 300.18  0.29  98.34  
F8 3.98 4.5 300.04 0.34  98.31 
F9 3.69 4.9 300.02 0.32 97.83 
F10 3.93 5.2 300.13 0.31  97.21  
 
Table 13: Results of in-vitro buoyancy study of Ketoconazole floating tablets 
Formulation Code Floating lag times (sec) Total Floating Time (hrs) 
F1 55s >8 
F2 35s >10 
F3 30s >12 
F4 75s >12 
F5 60s >12 
F6 80s >12 
F7 110s >10 
F8 95s >10 
F9 106s >12 
F10 105s >12 
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Figure 4: Photographs taken during in-vitro floating study of formula F8 in 200 ml 0.1 N HCl at different time intervals. 
 
Dissolution rate studies  
Table 14: In-vitro Drug Release Study of Ketoconazole Tablets 
Time % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 08.23 07.14 07.24 08.23 07.23 07.45 08.32 07.26 07.28 07.45 
2 12.32 10.23 11.45 10.45 10.45 11.23 12.23 11.87 12.56 11.23 
3 26.23 22.42 24.23 23.76 31.23 38.23 32.13 26.28 18.58 38.23 
4 42.45 40.32 45.23 44.23 48.23 46.32 47.14 38.21 40.28 46.32 
5 76.34 66.11 67.21 65.71 50.56 67.02 71.13 68.24 56.98 67.02 
6 82.23 77.33 75.11 82.34 55.00 88.13 91.23 89.12 73.98 88.13 
7 82.41 83.43 85.21 82.74 55.62 93.46 91.69 95.43 79.18 95.15 
8 82.55 97.13 87.13 83 56 99.13 92 99.25 84.16 99.13 
9 83 97.1 94.23 83.21 57.25 99.06 93 99.56 89.26 99.61 
10 84.21 97.23 99.26 83.5 57.85 99.81 94.56 99.76 94.56 99.87 
 
 
 
Figure 5: In vitro drug release study of Gastro retentive floating tablet 
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CONCLUSION 
Gastro-retention helps to provide better availability of new 
products with suitable therapeutic activity and substantial 
benefits for patients. This mode of administration would best 
achieve the known pharmacokinetic and pharmacodynamic 
advantages of CR-DFs of these drugs. The need for 
gastroretentive dosage forms (GRDFs) has led to extensive 
efforts in both academia and industry towards the 
development of such drug delivery systems. These efforts 
resulted in GRDFs that were designed, in large part, based on 
the following approaches. This study discusses the 
preparation of floating tablets of Ketoconazole. HPC, 
Xantham gum and gas-generating agent sodium bicarbonate 
was essential to achieve in vitro buoyancy. Addition of citric 
acid, to achieve buoyancy under the elevated pH of the 
stomach, caused an enhancement in drug release. All these 
results indicated that a low amount of floating agent and 
high amount of hydrophilic polymer favoured the sustained 
release of Ketoconazole from gastro retentive tablet 
formulations. A lesser floating and a prolonged floating 
duration could be achieved by varying the amount of 
effervescent and using different polymer combinations. The 
in vitro drug release profiles obtained for tablets (F10) made 
with combinations of HPC, xathan gum showed a prolonged 
floating duration (> 12hrs) which was a controlled release 
characteristic for 12 h. 
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